Table 3.

Summary of results from prospective, outcomes-based studies of real-world experience

	Standard RS cut-offs
	RS <18	RS 18–30	RS ≥31
SEER (all N+; N = 6768)
N (%)	3919 (64%)	2380 (35%)	469 (1%)
% CT “yes”/“no/unknown”	24%/76%	49%/51%	77%/23%
5-year BCSS (SE)	98.8% (0.3%)	97.3% (0.6%)	88.5% (2.4%)
p-value	<0.001
Clalit (N1mi/1–3N+; N = 709)
N (%)	379 (53%)	258 (36%)	72 (10%)
% CT/% no CT	7%/93%	40%/60%	86%/14%
5-year DR (95% CI)	3.2% (1.8%, 5.6%)	6.3% (3.9%, 10.1%)	16.9% (10.0%, 27.9%)
p-value	<0.001
5-year BCSM (95% CI)	0.5% (0.1%, 2.1%)	3.4% (1.7%, 6.7%)	5.7% (2.2%, 14.4%)
p-value	<0.001

BCSM breast cancer-specific mortality, BCSS breast cancer-specific survival, CI confidence interval, CT chemotherapy, DR distant recurrence, RS Recurrence Score result, SE standard error